Journal of Clinical Oncology
Articles in this Issue
Defining prostaglandin-driven dysregulation in <i>PIK3CA</i> -mutant colorectal cancers: A real-world multi-omic analysis.
3667 Background: PIK3CA mutations occur in a meaningful subset of colorectal cancers (CRC) and have be...
Mapping the ovarian cancer diagnostic journey in Israel: Results from a qualitative patient and clinician study.
e17570 Background: Ovarian cancer is the most lethal gynecologic malignancy worldwide, with survival declining sharply bet...
A multicenter single-arm study of induction EC/EP plus camrelizumab followed by maintenance camrelizumab plus apatinib in treatment-naive advanced or metastatic extrapulmonary neuroendocrine carcinoma.
4176 Background: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a poorly differentiated and highly aggressive maligna...
Clinicopathologic and molecular characterization of <i>ARID1A</i> -mutant solid tumors using paired tissue and liquid biopsy sequencing.
e15054 Background: ARID1A is a commonly altered chromatin-remodeling gene across solid tumors, with ro...
Survival outcomes of cabozantinib treatment with and without immune checkpoint inhibition in patients with heavily pretreated advanced sarcoma.
11551 Background: Cabozantinib is an oral tyrosine kinase inhibitor (TKI), with key targets including MET, VEGFR2, AXL, RE...
Real-world survival outcomes of surgical patients with squamous cell carcinoma of unknown primary of the head and neck: A National Cancer Database analysis.
e18142 Background: Squamous cell carcinoma of unknown primary (SC-CUP) of the head and neck is an infrequent disease, pres...
HRS-8080, an oral selective estrogen receptor degrader (SERD), in ER+/HER2− advanced breast cancer (aBC) with <i>ESR1</i> mutations ( <i>ESR1</i> m): Results from a first-in-human phase 1 trial.
1069 Background: HRS-8080 is a novel, potent oral SERD that binds ER with high affinity. We conducted a multi-part, first-...
Correlation of University of Texas Cancer Cachexia Staging (UTCCS) with clinical variables of systemic inflammation, nutritional status, and physical function in patients with cancer cachexia.
12046 Background: Cancer cachexia is a heterogenous syndrome characterized by ongoing loss of skeletal mass with or withou...
Surgical management and survival in pelvic osteosarcoma.
e23502 Background: Osteosarcoma is the most common malignant bone tumor in adolescents, young adults and older adults. Cur...
Progression-free survival as a surrogate for overall survival in ovarian cancer: Real-world evidence-based assessment and trial-level correlation.
e17587 Background: Progression-free survival (PFS) is widely used as a surrogate endpoint for overall survival (OS) in ova...
Lost in translation? Evaluating associations between English proficiency and next generation sequencing completion, and comparing understandability across different translation modalities among Spanish speakers with metastatic breast cancer.
1524 Background: Disparities in next-generation sequencing (NGS) utilization persist among patients with metastatic breast...
Perioperative durvalumab plus neoadjuvant chemoradiotherapy (CROSS) with and without tremelimumab in esophageal adenocarcinoma: The prospective phase II RICE trial (NCT04159974).
4083 Background: Anti-PD-(L)1 is effective in esophageal adenocarcinoma (EGA). The phase II RICE trial (NCT04159974) evalu...
Short-course radiotherapy followed by ivonescimab and CAPOX as neoadjuvant therapy for locally advanced rectal cancer: A single-arm, phase II trial.
e15652 Background: Short-course radiotherapy (SCRT) combined with chemotherapy as neoadjuvant therapy has been proven to i...
Oral darolutamide therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review and meta-analysis of phase III randomized controlled trials.
e17095 Background: Prostate cancer (PCa) is one of the most common malignancies among men globally and remains a leading c...
Cohort expansion of a phase I study of PLN-101095, a first-in-class dual α <sub>v</sub> β <sub>8</sub> /α <sub>v</sub> β <sub>1</sub> integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI).
TPS2690 Background: Transforming growth factor-β (TGF-β) drives immunosuppression and T-cell exclusion in solid tumors and...
Epidemiological trends in colorectal cancer mortality in South Asia, 1990–2023: A retrospective analysis and advanced machine learning forecasting to 2050.
e15591 Background: Colorectal cancer (CRC) is an emerging cause of cancer mortality in South Asia, yet comprehensive long-...
Treatment patterns and oncologic outcomes in patients with triple-negative (TN) lobular breast cancer.
605 Background: Triple-negative breast cancer (TNBC) with invasive lobular carcinoma (ILC) histology represents an exceedi...
Malnutrition and cachexia as drivers of failure-to-rescue in gynecologic cancer hospitalizations, 2016–2023.
11053 Background: Malnutrition and cancer cachexia are underrecognized in administrative data yet may identify hospitalize...
Association of sociodemographic, environmental, and health factors with early-onset cancer in a diverse urban cohort.
10592 Background: Early onset cancer (EOC; diagnosed before age 50) is rising globally, yet its drivers are incompletely u...
Prospective-retrospective HeCOG phase III trial validation of Polaris TME for the prediction of TILs from whole-slide images in high-risk early breast cancer.
557 Background: Tumor-infiltrating lymphocytes (TILs) are an established prognostic and predictive biomarker in early brea...
Engineering and preclinical evaluation of CXCR3-expressing, EGFR-targeted CAR-NK cells for tumor homing in non–small cell lung cancer and esophageal squamous cell carcinoma models.
e14515 Background: CAR-NK cell therapy for solid tumors is hindered by insufficient tumor infiltration. To address this li...
Older age as a predictor of post-transplant survival in newly diagnosed acute myeloid leukemia treated with HMA-venetoclax.
6530 Background: Venetoclax (Ven) plus hypomethylating agents (HMA) is standard frontline therapy for newly diagnosed AML...
RP2R dose selection of Tal + Tec for the treatment of EMD patients in the RedirecTT-1 study.
7524 Background: Talquetamab (Tal, anti-GPRC5D) and Teclistamab (Tec, anti-BCMA) are first-in-class bispecific antibodies...
Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.
TPS8662 Background: NSCLC has a heterogeneous biology frequently including high mutational burden, high EGFR expression an...
Objective responses and survival outcomes by grade 3-4 neutropenia in refractory metastatic colorectal cancer treated with trifluridine/tipiracil: Real-world evidence from the ReTrITA study.
e15611 Background: In refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (T), treatment-re...